Efficacy and safety of OBI‐1, an antihaemophilic factor VIII (recombinant), porcine sequence, in subjects with acquired haemophilia A

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2516|21|2|162-170

ISSN： 1351-8216

Source： HAEMOPHILIA, Vol.21, Iss.2, 2015-03, pp. : 162-170

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Improved joint health in subjects with severe haemophilia A treated prophylactically with recombinant factor VIII Fc fusion protein

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 77-84

John Wiley & Sons Inc

Access to resources Recommend Favorite

Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients

By  

HAEMOPHILIA, Vol. 24, Iss. 1, 2018-01 ,pp. : 104-112

John Wiley & Sons Inc

Access to resources Recommend Favorite

Integrated analysis of safety data from 12 clinical interventional studies of plasma‐ and albumin‐free recombinant factor VIII (rAHF‐PFM) in haemophilia A

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 791-798

John Wiley & Sons Inc

Access to resources Recommend Favorite

Results of a phase I/II open‐label, safety and efficacy trial of coagulation factor IX (recombinant), albumin fusion protein in haemophilia B patients

By  

HAEMOPHILIA, Vol. 21, Iss. 6, 2015-11 ,pp. : 784-790

John Wiley & Sons Inc

Access to resources Recommend Favorite

Ten‐year experience of recombinant activated factor VII use in surgical patients with congenital haemophilia with inhibitors or acquired haemophilia in Japan

By  

HAEMOPHILIA, Vol. 21, Iss. 3, 2015-05 ,pp. : 374-379

John Wiley & Sons Inc

Access to resources Recommend Favorite